Biohaven Reports Phase 2 Results for BHV-7000 in Major Depressive Disorder

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...

December 26, 2025 | Friday | News
Innovent’s TABOSUN® Plus TYVYT® Becomes World’s First Approved Dual-IO Neoadjuvant Therapy for MSI-H/dMMR Colon Cancer in China

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant...

December 26, 2025 | Friday | News
SN Bioscience’s SNB-101 Secures FDA Orphan Drug Designation for Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gast...

December 25, 2025 | Thursday | News
Hope Biosciences Reports Phase II Breakthrough Showing Significant Motor Improvement in Parkinson’s Disease

Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF)  shares positive top-line results of a Phase II clinical tri...

December 24, 2025 | Wednesday | News
Biosplice Doses First Patient in Phase 1 Trial of Cirtuvivint Plus Olaparib for Resistant Ovarian Cancer

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of CDC-like kinases (C...

December 24, 2025 | Wednesday | News
Mondego Bio Selects Lead PTPN2 Inhibitor ZE00-0388, Enters Clinical Stage

Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, announced the formal selection o...

December 23, 2025 | Tuesday | News
AusperBio Completes Phase III AUSHINE Trial Enrollment for Chronic Hepatitis B Therapy AHB-137

 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligon...

December 23, 2025 | Tuesday | News
FNIH Secures FDA Qualification of Hip Bone Mineral Density as Surrogate Endpoint in Osteoporosis Trials

Measuring change in bone mineral density, rather than fracture occurrence, promises to speed development of new drugs to treat osteoporosis. FNIH Bi...

December 22, 2025 | Monday | News
Takeda’s Zasocitinib Delivers Strong Phase 3 Wins in Plaque Psoriasis

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psor...

December 19, 2025 | Friday | News
Inhibrx Advances INBRX-106 and Ozekibart Programs, Expands Clinical Momentum Across Solid Tumors

Inhibrx Biosciences, Inc. a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology announced an update on the INBR...

December 18, 2025 | Thursday | News
Norgine Secures Exclusive Rights to Vir Biotechnology’s Hepatitis Delta Combination Therapy

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceutical...

December 18, 2025 | Thursday | News
Affibody Advances HER2 Radioligand Therapy ABY-271 to Next Phase of Clinical Study

Affibody AB announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) cand...

December 17, 2025 | Wednesday | News
Allink Biotherapeutics Secures $47M to Accelerate Next-Generation ADC and Multispecific Antibody Pipeline

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with stron...

December 17, 2025 | Wednesday | News
Neupulse Launches Drug-Free Wearable Offering New Hope for People Living With Tourette Syndrome

Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...

December 17, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close